Berotralstat for preventing recurrent attacks of hereditary angioedema: Appraisal consultation document
DRAFT guidance does not recommend use due to the uncertain clinical evidence and the most likely cost-effectiveness estimates being higher than what NICE considers a cost-effective use of NHS resources.
Source:
National Institute for Health and Care Excellence